Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events

    Research output: Contribution to journalReviewResearchpeer-review

  2. Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Pharmacokinetic evaluation of pemetrexed

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review

    Research output: Contribution to journalReviewResearchpeer-review

  2. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Opening of ATP sensitive potassium channels causes migraine attacks with aura

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Dose-response curves for efficacy and tolerability are the important determinants for the choice of doses of acute migraine drugs. Areas covered: Dose-response curves for the efficacy of seven triptans (5-HT1B/1D receptor agonists), a 5-HT1F receptor agonist (lasmiditan) and four oral calcitonin-gene related peptide receptor antagonists (telcagepant, MK-3207, BI 44370 TA and BMS-927711) in placebo-controlled trials were reviewed. In addition, dose-response curves for adverse events (AEs) were reviewed. Expert opinion: For most triptans, the dose-response curve for efficacy is flat, whereas AEs often increase with increasing doses. The two other groups of drugs also have flat dose-response curves for efficacy. Overall, the triptans still have the most favorable efficacy-tolerability profile. Current acute antimigraine drugs do not fulfill the expectations of the patients, and thus, there are many unmet needs. Although upcoming drugs may not be superior to triptans, migraine patients will potentially benefit greatly from these, especially patients who are triptan non-responders and patients with cardiovascular disease.

Original languageEnglish
JournalExpert Opinion on Drug Metabolism & Toxicology
Volume11
Issue number9
Pages (from-to)1409-1418
ISSN1742-5255
DOIs
Publication statusPublished - 22 Jun 2015

ID: 45515180